Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income from Continuing Operations (2023 - 2025)

CG Oncology's Income from Continuing Operations history spans 3 years, with the latest figure at 41256000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 29.72% year-over-year to 41256000.0; the TTM value through Dec 2025 reached 160843000.0, down 82.69%, while the annual FY2025 figure was 160843000.0, 82.69% down from the prior year.
  • Income from Continuing Operations reached 41256000.0 in Q4 2025 per CGON's latest filing, up from 43708000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 8675000.0 in Q1 2023 to a low of 43708000.0 in Q3 2025.
  • Average Income from Continuing Operations over 3 years is 24785500.0, with a median of 19656500.0 recorded in 2024.
  • The largest YoY upside for Income from Continuing Operations was 29.72% in 2025 against a maximum downside of 119.05% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 16551000.0 in 2023, then crashed by 92.16% to 31804000.0 in 2024, then decreased by 29.72% to 41256000.0 in 2025.
  • Per Business Quant, the three most recent readings for CGON's Income from Continuing Operations are 41256000.0 (Q4 2025), 43708000.0 (Q3 2025), and 41422000.0 (Q2 2025).